Tag - TOCA

Developments

Tocagen fails Phase 3 trial in recurrent brain cancer

Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall survival, compared with...

September 12, 2019

Markets

SVB Leerink starts Tocagen at MP; PT $11

SVB Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with a “market perform” rating and $11 price target. The stock closed at $10.26 on April 12. Tocagen is advancing a cancer-selective gene therapy platform that is...

April 15, 2019

Markets

HCW starts Tocagen at buy; PT $14.50

H.C. Wainwright initiated coverage of Tocagen (NASDAQ:TOCA) with a “buy” rating and price target of $14.50. The stock closed at $9.64 on June 8. Analyst Swayampakula Ramakanth writes that the company’s lead product...

June 11, 2018

Tag - TOCA

Tocagen fails Phase 3 trial in recurrent brain cancer

SVB Leerink starts Tocagen at MP; PT $11

HCW starts Tocagen at buy; PT $14.50

General

More